Serious GI Risks Found in Ozempic and Wegovy Weight-Loss Drugs

A large-scale study published in JAMA has found that weight loss drugs like Wegovy and Ozempic, which belong to the class of GLP-1 receptor agonists, may increase the risk of stomach paralysis (gastroparesis) and other serious gastrointestinal conditions. The study analyzed health insurance claim records of approximately 16 million non-diabetic patients prescribed these drugs over a 14-year period. The researchers found that those taking GLP-1 agonists were more likely to develop stomach paralysis, pancreatitis, and bowel obstruction compared to those taking another weight loss drug. The study highlights the need for updated warning labels and informed decision-making by patients considering the use of these medications.